Blood test may predict liver cancer comeback and immunotherapy success

NCT ID NCT07350824

Not yet recruiting Knowledge-focused Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a blood test that detects tiny bits of tumor DNA (called minimal residual disease) can predict if liver cancer will come back after surgery. Researchers will test 276 patients before and after surgery to see if the test can also identify who might benefit from additional immunotherapy. The goal is to find a better way to monitor patients and guide treatment decisions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MINIMAL RESIDUAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma Neoplasm, Residual Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC MINIMAL RESIDUAL DISEASE RECURRENCE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Division of Hepato-Pancreato-Biliary Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430000, China